Heart failure market to increase 5.2% CAGR by 2032

It is seen to increase to US$53b in 2032.

The market for heart failure is seen to grow from US$31.9b in 2022 to $53b in 2032 across seven major markets including the US, France, Germany, Italy, Spain, the UK, and Japan, GlobalData said in its latest forecast.

GlobalData also anticipates the launch of pipeline drugs Tirzepatide, omecamtiv mecarbil, Neucardin, and Kerendia (finerenone) to raise the market size and further promote the growth of the heart failure market.

Kajal Jaddoo, senior pharma analyst at GlobalData, said the pressure for pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. 

“Companies are approaching the HF market with the strategies of optimizing treatment safety and compliance, as well as developing novel drug classes,” it said.

Jaddoo also pointed out that it will be easier for new drug entrants to capture HF market share if they offer a novel mechanism of action or help to improve compliance.